Bhutani T, Jayade S, Rege S, Penton H, Patel V, Kalirai S, Wolin D, Boyle K, Seigel L. Evaluating prevalence and consequence of residual disease in individuals with psoriasis receiving apremilast treatment: results from a US patient survey. J Dermatolog Trea. 2024 Jun 24;35(1):2366532. doi: 10.1080/09546634.2024.2366532
Myers K, Silverberg JI, Parasuraman S, Pierce A, Eichenfield LF, Poulos C. Treatment preferences among patients with mild-to-moderate atopic dermatitis. J Dermatolog Trea. 2023 Dec;34(1):2215356. doi: 10.1080/09546634.2023.2215356.
Kwatra SG, Lio P, Weidinger S, Calimlim B, Ladizinski B, Vigna N, Botha W, Mansfield C. Patient preferences for atopic dermatitis treatments: a discrete choice experiment. J Dermatolog Trea. 2023 Dec 1;34(1):2222201. doi: 10.1080/09546634.2023.2222201
Jia X, Zhao Y, Carrico J, Brodtkorb T-H, Mendelsohn AM, Lowry S, Feldman S, Wu JJ, Armstrong AW. Cost-effectiveness of tildrakizumab for the treatment of moderate-to-severe psoriasis in the United States. J Dermatolog Trea. 2022 Mar;33(2):740-8. doi: 10.1080/09546634.2020.1773382
Ervin C, Crawford R, Evans E, Feldman SR, Zeichner J, Zielinski M, Cappelleri JC, DiBonaventura M, Takiya L, Myers DE. Patient and caregiver preferences on treatment attributes for atopic dermatitis. J Dermatolog Trea. 2021 Oct 6;1-9. doi: 10.1080/09546634.2021.1940810
Feldman SR, Poulos C, Gilloteau I, Mange B, Boehm K, Boeri M, Naatz M, Augustin M. Exploring determinants of psoriasis patients' treatment choices: a discrete-choice experiment study in the United States and Germany. J Dermatolog Trea. 2021 Feb 3;1-10. doi: 10.1080/09546634.2020.1839007
Layton JB, Anderson-Smits C, Ritchey ME, Chavan S, Souayah N. Treatment patterns of US patients with chronic inflammatory demyelinating polyradiculoneuropathy. Poster presented at the 2020 Virtual American Association of Neuromuscular and Electrodiagnostic Medicine Annual Meeting; October 2020. [abstract] Muscle Nerve. 2020 Oct; p.126.
Martin SA, Brown TM, Fehnel S, Deal LS, Katz EG, Chiou CF. The atopic dermatitis itch scale: development of a new measure to assess pruritus in patients with atopic dermatitis. J Dermatolog Trea. 2020 Aug;31(5):484-30708. doi: 10.1080/09546634.2020.1713971
Wu JJ, Jia X, Zhao Y, Carrico J, Brodtkorb TH, Mendelsohn A, Lowry A, Feldman SR, Armstrong A. Comparative cost-effectiveness of tildrakizumab and other commonly used treatments for moderate-to-severe psoriasis. J Dermatolog Trea. 2020 Apr 1;1-8. doi: 10.1080/09546634.2019.1698700
Giner-Soriano M, Teixido C, Marsal JR, Diez O, Pera H, Vlacho B, Morros R, working group for the clinical trial IJG-KOH-2014. Randomized placebo-controlled clinical trial on efficacy and safety of topical 10% Potassium hydroxide for molluscum contagiosum treatment in children. J Dermatolog Trea. 2019 Dec;30(8):750-6. doi: 10.1080/09546634.2019.1573305
Fernandez M, Mordin M, Neighbors M, Tzivelekis S. A targeted literature review on the burden of chronic inflammatory demyelinating polyneuropathy. Poster presented at the 2019 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Conference; October 16, 2019. Austin, TX. [abstract] Muscle Nerve. 2019 Sep; p.112.
Elewski BE, Puig L, Mordin M, Gilloteau I, Sherif B, Fox T, Gnanasakthy A, Papavassilis C, Strober BE. Psoriasis patients with Psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumab. J Dermatolog Trea. 2017 Sep;28(6):492-9. doi: 10.1080/09546634.2017.1307464
Korman NJ, Sofen H, Fretzin S, Rich P, Zhao Y, Herrera V, Nyirady J, Williams N, Mordin M, Tyring S. Secukinumab provides better relief from the impact of psoriasis on daily activities and personal relationships than etanercept: results of two phase 3 placebo-controlled randomized clinical trials in moderate-to-severe psoriasis. J Dermatolog Trea. 2017 Aug;28(5):384-9.
Williams V, Coles T, Gnanasakthy A, DeMuro C, Yarr S, Williams NJ, Lowes L, Alfano L, Tseng B. Psychometric validation of a patient-reported measure of physical functioning in sporadic inclusion body myositis. Muscle Nerve. 2016 Oct 13;54(4):658-65. doi: 10.1002/mus.25080
DeMuro C, Lewis S, Lowes L, Alfano L, Tseng B, Gnanasakthy A. Development of the sporadic inclusion body myositis physical functioning assessment (sIFA). Muscle Nerve. 2016 Oct;54(4):653-7. doi: 10.1002/mus.25079
Pariser D, Schenkel B, Carter C, Farahi K, Brown TM, Ellis CN. A multicenter, non-interventional study to evaluate patient-reported experiences of living with psoriasis. J Dermatolog Trea. 2016 Jan;27(1):19-26. doi: 10.3109/09546634.2015.1044492